Disease Landscape and Forecast Insights

The chronic obstructive pulmonary disease (COPD) market continues to gradually shift away from LABA/ICS FDCs toward LABA/LAMA FDCs and LABA/LAMA/ICS FDCs, but current and emerging generics are…

The schizophrenia therapy market remains very competitive; atypical and typical antipsychotics play a dominant role. While the continued generic erosion of atypical antipsychotics influences…

Vaccination programs have had a revolutionary impact on global public health, not only dramatically reducing the incidence of infectious disease but also reducing childhood and adult mortality and…

Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…

The treatment landscape for endometrial carcinoma is rapidly evolving, driven by the growing adoption of immune checkpoint inhibitors and advancements in molecular classification. Although…

The Crohn’s disease (CD) therapy market will grow steadily over the next 10 years as a result of the increasing use of biologics / targeted oral therapies. The well-established TNF-alpha…

Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems. SLE symptoms range from general malaise to serious CNS and renal manifestations. Hydroxychloroquine…

Biologics approved to treat immune indications (e.g., rheumatoid arthritis, Crohn’s disease) are among the most commercially successful biopharmaceutical products and offer a great opportunity to…

Chronic kidney disease (CKD) encompasses a set of heterogeneous disorders that gradually damage the kidneys’ structure or function. To manage CKD and delay its progression to end-stage kidney…

The treatment of multiple myeloma is becoming increasingly complex. Sanofi’s Sarclisa received a label expansion for the first-line treatment of autologous stem-cell transplantation-ineligible…

Migraine, which afflicts approximately 73 million people in the major pharmaceutical markets according to Clarivate Epidemiology, is a heterogeneous condition requiring individualized treatment…

Ever since Novartis’s Kymriah became the first chimeric antigen receptor (CAR) T-cell therapy approved by the FDA for a cancer indication (acute lymphoblastic leukemia) in 2017, this class of…